Home patients
 

Keywords :   


Tag: patients

A better way to care for dementia patients

2018-03-16 01:15:11| BBC News | Business | UK Edition

Infrared technology and artificial intelligence offer a better way to take care of dementia patients. It can scan their vital signs 24 hours a day.

Tags: care patients dementia

 

Insurers should do more to help cancer patients, says FCA

2017-06-20 13:37:29| BBC News | Business | UK Edition

In one case a nurse with cancer was quoted 2,800 for travel insurance for a holiday to Dubai.

Tags: says cancer patients insurers

 
 

Jakarta bird flu hospital overwhelmed with patients

2017-06-19 11:55:28| A1AWEB Internet Advertising, Website Creation, Marketing, Promotion, SEO

Tags: hospital patients bird flu

 

Locked-in ALS patients get a voice thanks to this new mind-reading machine

2017-02-07 20:50:34| Extremetech

Researchers from Europe have used a brain-computer interface to communicate with four completely locked-in ALS patients. The post ‘Locked-in’ ALS patients get a voice thanks to this new mind-reading machine appeared first on ExtremeTech.

Tags: this als machine voice

 

European Commission Approves KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations

2017-01-31 22:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Approval Based on Data Showing Improved Overall Survival and Progression-Free Survival with KEYTRUDA Compared to Chemotherapy First Anti-PD-1 Therapy Approved in Europe for Previously Untreated Patients with Metastatic NSCLC KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tumor mutations. Language: English Contact: For MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more

Tags: high positive cell treatment

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] next »